On 9 September 2026, Fountain Set (Holdings) Limited (00420.HK) announced that an indirect wholly-owned subsidiary proposed to acquire an 81% interest in a Vietnam textile company for a cash consideration of USD 27,945,000 (approximately HKD 219,089,000); the target's 100% equity was valued at approximately RMB 240,653,200 on an asset-based basis as of 30 April 2026, with consideration payable in three instalments; the acquisition constitutes a major transaction subject to shareholders' approval, with a circular expected by 31 October 2026.
On 8 September 2026, Ascletis Pharma Inc. (01672.HK) announced in a voluntary announcement that it had initiated a US Phase I study of ASC36 oral tablets, an oral amylin receptor agonist peptide, for obesity following FDA IND approval, marking its fourth peptide Phase I study this year; in non-human primates, once-daily dosing for seven days achieved up to 13.2% mean weight loss versus baseline, with steady-state absolute oral bioavailability of 6% to 8%.
On 7 September 2026, DEEP SOURCE (00990.HK) announced that its AI data center (AIDC) project in Malaysia has been approved by MITI, with certain water and electricity conditions being implemented.
On 6 September 2026, FOSUN PHARMA (02196.HK) announced that its subsidiary Fosun Pharma Singapore sold 9.897 million shares (6.00%) of India's Gland Pharma on 4 September 2026 for approximately USD 294 million, at a 2.72% discount to the previous closing price. Post-transaction, the group's stake falls to approximately 45.76% while it remains the controlling shareholder; proceeds are designated for R&D investment, share buybacks and debt repayment, with settlement expected on 7 September 2026 India time.
On 7 September 2026, CLOVER BIO-B (02197.HK) reported positive Phase II data for respiratory combination vaccine candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) among 420 elderly subjects in Australia.
On 6 September 2026, Anton Oilfield Services Group (03337.HK) announced that it obtained approval from the Iraqi Ministry of Oil and signed a long-term cooperation agreement with the State Oil Marketing Company (SOMO) on the same day, securing the crude oil sales qualification and the right to lift crude from the Iraqi national oil company's self-operated oilfields, becoming Iraq's designated crude oil export sales partner and the only independent Chinese oil and gas energy company in the Iraqi market with simultaneous qualifications in oilfield services, resource development and crude sales.
This week's two main lines of overseas expansion were global licensing of innovative drugs and Hong Kong listings. HUTCHMED out-licensed global rights to its KRAS-EGFR conjugate drug to GSK, with milestone payments totalling up to USD 1.295 billion; SBP GROUP licensed TQB2102 to Cipla for up to USD 123 million; and KEYMED BIO-B reached an exclusive licensing deal for stapokibart covering 18 countries and regions. On the financing front, SHEIN-W listed at HKD 48.56 per share with total proceeds of approximately HKD 13.596 billion, ANJI TECHNOLOGY and AMLOGIC advanced their H-share offerings, and LONGSYS priced its H shares at HKD 236. MAN WAH HLDGS raised its stake in UK-based DFS to 8.58% for approximately HKD 132 million, HONGHUA GROUP signed RMB 600 million in drilling rig orders in the Middle East, and BYD COMPANY and GEELY AUTO sustained export growth in August.
On September 3, 2026, SBP GROUP (01177.HK) announced that TQB6426, a national Class 1 innovative drug and a GPC3-targeting antibody-drug conjugate independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., had received IND approval from the US FDA for advanced malignant tumors. GPC3 is highly expressed in hepatocellular carcinoma and no GPC3-targeting ADC has been approved worldwide; the group will accelerate the Phase I clinical trial to evaluate the drug's safety, tolerability, pharmacokinetic profile and preliminary efficacy.
On September 3, 2026, CMS (00867.HK) announced that its subsidiary Dermavon Holdings Limited had obtained NMPA approval and a drug registration certificate for ruxolitinib phosphate cream (Bailutuo) in mild-to-moderate atopic dermatitis, the product's second approved indication in China following vitiligo in January 2026. Phase III data showed 8-week IGA response of 63.0% versus 9.2% for placebo and EASI 75 response of 78.0% versus 15.4% (P<0.001); the product was in-licensed through a collaboration and license agreement with Incyte signed in December 2022.
On 2 September 2026, Keymed Biosciences Inc. (KEYMED BIO-B, 02162.HK) announced an exclusive license agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the registration and commercialization of its in-house developed IL-4Rα monoclonal antibody Stapokibart injection (Kangyueda) in 18 countries and regions — 11 in Southeast Asia, 5 in Central Asia, plus Hong Kong and Macao; Keymed will receive an upfront payment, milestone payments and high-double-digit royalties based on net sales, and will continue to handle manufacturing and supply.
On 2 September 2026, KEYTOP PARKING (02272.HK) announced that it had filed an application with the CSRC for H-share full circulation, planning to convert all of its 2,857,040 unlisted shares with a par value of RMB 1.0 each into H shares for listing and trading on the Main Board of the Stock Exchange. No further shareholders' meeting is required for the conversion and listing, implementation details are yet to be finalized, and completion remains subject to approvals from relevant domestic and overseas regulators.
On 2 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637.HK) announced that HX9428 had filed a Phase IIa IND for diabetic macular edema with the CDE of NMPA on 31 August 2026; the Phase I dose-escalation study in neovascular age-related macular degeneration was fully completed, with 13 patients finishing 24 weeks of dosing without additional intravitreal injections and average visual acuity improvement exceeding 5 letters. The drug has received Fast Track Designation from the US FDA.
On 2 September 2026, HONGHUA GROUP (00196.HK) announced that its subsidiary Sichuan Honghua has signed drilling rig sales agreements with a Middle East customer totalling RMB 600 million, with the rigs to be equipped with self-developed intelligent systems.
On 2 September 2026, PEGBIO CO-B (02565.HK) announced a material transfer agreement with Korean biotech SN BioScience to apply its SNA long-acting delivery platform to three metabolic disease peptide candidates including APGP6.
NewTimeSpace News: On 1 September 2026, LAEKNA-B (02105.HK) announced that the first subject has been enrolled in the Phase I clinical study of LAE118, a novel PI3Kα pan-mutation selective inhibitor, for advanced solid tumours in China; the drug has received IND approval from the US FDA and CDE, and in June 2026 the Group entered into an exclusive licence agreement with Vasque Bio providing for payments of up to USD 527 million.
NewTimeSpace News: On August 31, 2026, Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary CTTQ has entered into an exclusive license and supply agreement with Cipla for TQB2102, a HER2 bispecific ADC, granting Cipla an exclusive license to develop and commercialize the drug in India, South Africa and five other emerging markets, with milestone payments of up to USD 123 million plus double-digit royalties. This is the second regional licensing collaboration for TQB2102; the two collaborations have together brought approximately USD 30 million in upfront and milestone payments.
